{"id":"ad26-zebov-mva-bn-filo","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL5314975","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The Ad26.ZEBOV vaccine is a recombinant adenovirus vector-based vaccine that expresses the Zaire ebolavirus glycoprotein. The MVA-BN-Filo vaccine is a modified vaccinia virus Ankara-based vaccine that expresses the filovirus glycoprotein.","oneSentence":"Replicon-based vaccine targeting Zaire ebolavirus","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:19:03.820Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Ebola"}]},"trialDetails":[{"nctId":"NCT02891980","phase":"PHASE1","title":"A Safety Trial to Test MVA-BN(R)-Filo and Ad26.ZEBOV Vaccines in Healthy Volunteers","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2017-03-24","conditions":"Ebola Disease, Marburg Disease","enrollment":65},{"nctId":"NCT02543268","phase":"PHASE3","title":"A Study to Evaluate the Immunogenicity, Safety and Tolerability of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants","status":"COMPLETED","sponsor":"Crucell Holland BV","startDate":"2015-09-21","conditions":"Healthy","enrollment":329},{"nctId":"NCT04228783","phase":"PHASE3","title":"A Study of 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN-Filo in Adult Participants","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2020-02-18","conditions":"Ebola","enrollment":974},{"nctId":"NCT03929757","phase":"PHASE2","title":"A Study of 2-dose Vaccination Regimen of Ad26.ZEBOV and MVA-BN-Filo in Infants","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2019-08-19","conditions":"Ebola Virus Disease","enrollment":108},{"nctId":"NCT02543567","phase":"PHASE3","title":"A Study to Evaluate A Range of Dose Levels of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2015-09-21","conditions":"Healthy","enrollment":525},{"nctId":"NCT05284097","phase":"PHASE2","title":"Ad26.ZEBOV, MVA-BN-Filo Vaccination in Children and Adults Previously Vaccinated With Control in the EBOVAC-Salone Study","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2022-09-19","conditions":"Virus Diseases, Hemorrhagic Fever, Ebola, Infections","enrollment":133},{"nctId":"NCT02598388","phase":"PHASE2","title":"Safety, Tolerability and Immunogenicity Study of 2-dose Heterologous Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2015-12-10","conditions":"Hemorrhagic Fever, Ebola","enrollment":578},{"nctId":"NCT04556526","phase":"PHASE3","title":"A Study of a 2-dose Ebola Vaccine Regimen of Ad26.ZEBOV Followed by MVA-BN-Filo in Healthy Pregnant Women","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2020-10-05","conditions":"Healthy","enrollment":4031},{"nctId":"NCT02876328","phase":"PHASE2","title":"Partnership for Research on Ebola VACcinations","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2017-03-27","conditions":"Ebola Virus Disease","enrollment":4789},{"nctId":"NCT02661464","phase":"PHASE3","title":"Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo","status":"TERMINATED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2016-05-31","conditions":"Hemorrhagic Fever, Ebola","enrollment":677},{"nctId":"NCT04711356","phase":"PHASE2","title":"Ad26.ZEBOV Booster in Children Previously Vaccinated With Ad26.ZEBOV and MVA-BN-Filo (EBOVAC Booster Study)","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2021-07-08","conditions":"Ebola Virus Disease","enrollment":50},{"nctId":"NCT05064956","phase":"PHASE2","title":"Ad26.ZEBOV Booster in HIV+ Adults Previously Vaccinated With Ad26.ZEBOV/MVA-BN-Filo (EBOVAC HIV+ Booster Study)","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2021-10-06","conditions":"Ebola Virus Disease, Ebola, Hiv","enrollment":26},{"nctId":"NCT03820739","phase":"","title":"EBOVAC-Salone Extension","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2019-07-22","conditions":"Ebola Virus Disease","enrollment":653},{"nctId":"NCT04186000","phase":"PHASE2","title":"Study to Evaluate the Immunogenicity and Safety of a Heterologous Vaccine Regimen Against Ebola","status":"COMPLETED","sponsor":"Universiteit Antwerpen","startDate":"2019-12-18","conditions":"Ebola Virus Disease","enrollment":699},{"nctId":"NCT02509494","phase":"PHASE3","title":"Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-Filo","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2015-09-30","conditions":"Ebola Virus Disease","enrollment":1023},{"nctId":"NCT02564523","phase":"PHASE2","title":"Safety, Tolerability and Immunogenicity Study of 3 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo in Healthy Adults, Children and Human Immunodeficiency Virus Positive (HIV+) Adults","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2015-11-06","conditions":"Hemorrhagic Fever, Ebola","enrollment":1075},{"nctId":"NCT04152486","phase":"PHASE3","title":"Effectiveness and Safety of a Heterologous, Two-dose Ebola Vaccine in the DRC","status":"UNKNOWN","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2019-11-14","conditions":"Ebola Virus Disease","enrollment":20426},{"nctId":"NCT04028349","phase":"PHASE2","title":"ZEBOVAC (Ebola Vaccine Trial, Ad26.ZEBOV/MVA-BN-Filo)","status":"COMPLETED","sponsor":"MRC/UVRI and LSHTM Uganda Research Unit","startDate":"2019-08-01","conditions":"Ebola Virus Disease","enrollment":800},{"nctId":"NCT02416453","phase":"PHASE2","title":"A Study to Assess Safety, Tolerability, and Immunogenicity of Three Heterologus 2-dose Regimens of the Candidate Prophylactic Vaccines for Ebola in Healthy Adults","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2015-06-15","conditions":"Ebola Viral Disease","enrollment":423},{"nctId":"NCT03140774","phase":"","title":"Persistence of the Immune Response After Immunisation With Ebola Virus Vaccines","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2017-05-17","conditions":"Ebola Virus Disease","enrollment":126},{"nctId":"NCT02860650","phase":"PHASE1","title":"A Study to Evaluate Safety, Tolerability, and Immunogenicity of Heterologous Prime-boost Regimens Using the Multivalent Filovirus Vaccines Ad26.Filo and MVA-BN-Filo Administered in Different Sequences and Schedules in Healthy Adults","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2016-08","conditions":"Healthy","enrollment":72},{"nctId":"NCT02325050","phase":"PHASE1","title":"A Safety and Immunogenicity Study of Heterologous and Homologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2015-01-08","conditions":"Healthy","enrollment":164},{"nctId":"NCT02313077","phase":"PHASE1","title":"A Safety and Immunogenicity Study of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants","status":"COMPLETED","sponsor":"Crucell Holland BV","startDate":"2014-12-17","conditions":"Healthy","enrollment":87},{"nctId":"NCT02376426","phase":"PHASE1","title":"A Study to Evaluate the Safety and Immunogenicity of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants","status":"COMPLETED","sponsor":"Crucell Holland BV","startDate":"2015-03","conditions":"Healthy","enrollment":72},{"nctId":"NCT02376400","phase":"PHASE1","title":"A Study to Assess the Safety and Immunogenicity of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants","status":"COMPLETED","sponsor":"Crucell Holland BV","startDate":"2015-04","conditions":"Healthy","enrollment":78}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":44,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["VAC52150"],"phase":"phase_2","status":"active","brandName":"Ad26.ZEBOV, MVA-BN-Filo","genericName":"Ad26.ZEBOV, MVA-BN-Filo","companyName":"London School of Hygiene and Tropical Medicine","companyId":"london-school-of-hygiene-and-tropical-medicine","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Replicon-based vaccine targeting Zaire ebolavirus Used for Ebola.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}